RxDoctor Payments Data

Olivia Marlowe, PA

Physician Assistant · Nashville, TNNPI 1205404514

Payments from drug & device makers

$5,594in general payments, 2019–2025

Across 238 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$987
  • AbbVie$356
  • Novartis$293
  • AstraZeneca$289
  • Biogen$288
  • ANI Pharmaceuticals, Inc.$251
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$5,36996%
  • Education$2254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,594 in reported general payments places this provider in the 90th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$75,379
Medicare patients
373
Services billed
784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate25$31,413
QuliptaAtogepant20$21,333
BotoxOnabotulinumtoxina13$20,110
Aimovig AutoinjectorErenumab-Aooe27$19,992
Emgality PenGalcanezumab-Gnlm14$14,601
UbrelvyUbrogepant13$12,886
Lacosamide44$6,821
Pregabalin117$4,056
Levetiracetam108$3,056
Carbidopa-LevodopaCarbidopa/Levodopa161$2,831
Memantine Hcl237$2,554
Gabapentin211$2,347
Donepezil Hcl242$1,910
Primidone123$1,852
Oxcarbazepine45$1,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Botox, Ubrelvy$356$54,32946 claims
PfizerNurtec Odt$225$31,41325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →